AXNX Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 1.85%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $205,523.01

Axonics Insider Trading History Chart

This chart shows the insider buying and selling history at Axonics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M-$5M$0$5M$10MTotal Insider BuyingTotal Insider Selling

Axonics Share Price & Price History

Current Price: $70.98
Price Change: +0.30 (1.20%)
As of 11/15/2024 01:00 AM ET

This chart shows the closing price history over time for AXNX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

SEC Filings (Institutional Ownership Changes) for Axonics (NASDAQ:AXNX)

99.48% of Axonics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at AXNX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$4.14MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200M$0$200MTotal InflowsTotal Outflows
Axonics logo
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Read More on Axonics

Today's Range

Now: $70.98
Low: $70.98
High: $70.98

50 Day Range

MA: $70.61
Low: $69.66
High: $70.98

52 Week Range

Now: $70.98
Low: $66.32
High: $71.05

Volume

N/A

Average Volume

420,950 shs

Market Capitalization

$3.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Who are the company insiders with the largest holdings of Axonics?

Axonics' top insider investors include:
  1. Raymond W Cohen (CEO)
  2. John Woock (EVP)
  3. Alfred J Ford Jr (Insider)
  4. Kari Leigh Keese (CFO)
  5. Karen Noblett (Insider)
  6. Danny L Dearen (CFO)
Learn More about top insider investors at Axonics.